‘Swift’ Vascepa Victory Puts Hikma And Reddy’s In Pole Position
But Analyst Calls Generic Threat ‘Overstated’
Executive Summary
Hikma and Dr Reddy’s Laboratories are weighing launches of their generics to Amarin’s Vascepa after the US Court of Appeals for the Federal Circuit upheld a favorable lower court ruling. The originator said it would take its appeal to the next level and continued to raise doubts over supply capacity.
You may also be interested in...
Hikma Launches US Vascepa Rival As Amarin Appeal Denied
Hikma has launched its US rival to Vascepa, after the US Court of Appeals for the Federal Circuit refused a request by Amarin for an “en banc” rehearing of key litigation.
Hikma Is Keeping On Top Of COVID ‘Rollercoaster’
Careful supply-chain planning and an agile, flexible approach to manufacturing have been key in helping Hikma to stay on top of the “rollercoaster ride” provided by the COVID-19 pandemic in 2020 so far, according to CEO Siggi Olafsson.
Supply Chain Constraints ‘Will Limit Vascepa Threat’
Supply is the million-dollar question for Vascepa ANDA sponsors, with Dr Reddy’s and Hikma receiving a further green light to introduce their generics into the US market.